Gilead Sciences (GILD) just cleared an important milestone: its once daily bictegravir and lenacapavir combo matched Biktarvy ...

Wondering if Gilead Sciences is still a smart buy after its big run, or if the stock has already priced in the good news?

Gilead Sciences, Inc. announced that Keeley Wettan has been appointed executive vice president and general counsel, Legal & Compliance, effective immediately, the biopharmaceutical company said ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General ...

With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...

Gilead Sciences said on Monday its experimental HIV treatment met the main goal and was found to be statistically ...

Gilead and Arcellx reported promising data for their CAR-T therapy anito-cel at the annual American Society of Hematology ...

Arcus will now refocus its efforts outside of TIGIT, specifically on its asset casdatifan, an HIF-2a inhibitor once backed by Gilead, as well as its earlier stage small-molecule inflammatory and ...

Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...

The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT ...

Gilead Sciences said its in-development HIV treatment met the primary endpoint of a recent late-stage clinical trial. The biopharmaceutical company said Monday that the treatment, a once-daily single ...

Gilead Sciences Inc. has appointed Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance effective ...